WPD Pharmaceuticals Inc. (WPDPF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 680.83 Thousand USD | 66.4% |
| 2022 | 409.15 Thousand USD | -91.26% |
| 2021 | 4.68 Million USD | 278.24% |
| 2020 | 1.23 Million USD | 43.19% |
| 2019 | 864.47 Thousand CAD | -61.62% |
| 2018 | 2.25 Million USD | 2751.15% |
| 2017 | 78.99 Thousand USD | -61.75% |
| 2016 | 206.49 Thousand USD | 403.6% |
| 2015 | 41 Thousand USD | 50.64% |
| 2014 | 27.21 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 730.65 Thousand USD | 9.69% |
| 2024 Q2 | 693.28 Thousand USD | -4.14% |
| 2023 Q4 | 680.83 Thousand USD | 4.51% |
| 2023 Q3 | 651.44 Thousand USD | 3.74% |
| 2023 Q2 | 627.94 Thousand USD | 43.14% |
| 2023 Q1 | 438.7 Thousand USD | -20.9% |
| 2023 FY | 680.83 Thousand USD | 66.4% |
| 2022 Q4 | 554.64 Thousand CAD | 0.0% |
| 2022 FY | 409.15 Thousand USD | -91.26% |
| 2021 Q1 | 2.14 Million USD | 73.59% |
| 2021 FY | 4.68 Million USD | 278.24% |
| 2021 Q3 | 3.26 Million USD | 19.4% |
| 2021 Q2 | 2.73 Million USD | 27.44% |
| 2021 Q4 | 4.68 Million USD | 43.19% |
| 2020 Q3 | 1.31 Million USD | 220.5% |
| 2020 FY | 1.23 Million USD | 43.19% |
| 2020 Q4 | 1.23 Million USD | -5.88% |
| 2020 Q2 | 410.36 Thousand USD | 0.0% |
| 2019 FY | 864.47 Thousand CAD | -61.62% |
| 2018 FY | 2.25 Million USD | 2751.15% |
| 2017 FY | 78.99 Thousand USD | -61.75% |
| 2016 FY | 206.49 Thousand USD | 403.6% |
| 2015 FY | 41 Thousand USD | 50.64% |
| 2014 FY | 27.21 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2381.807% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 92.808% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.061% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 15.821% |
| Rebus Holdings, Inc. | 5.24 Million USD | 87.012% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.846% |
| Qrons Inc. | 1.48 Million USD | 54.267% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 44.477% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.091% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1423.255% |
| Skye Bioscience, Inc. | 14.07 Million USD | 95.162% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.723% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 92.895% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -61.5% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.639% |
| Intellipharmaceutics International Inc. | 12 Million USD | 94.331% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 82.323% |
| Mesoblast Limited | 188.44 Million USD | 99.639% |
| Marizyme, Inc. | 26.67 Million USD | 97.448% |
| Genus plc | 485 Million USD | 99.86% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 88.347% |
| Pharming Group N.V. | 244.07 Million USD | 99.721% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 66.13% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 72.943% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 82.083% |
| ContraFect Corporation | 32.53 Million USD | 97.907% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 65.637% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 82.213% |
| IMV Inc. | 37.93 Million USD | 98.205% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 94.22% |
| MultiCell Technologies, Inc. | 1617.67 USD | -41987.323% |
| ONE Bio Corp. | 27.49 Million USD | 97.524% |
| Accustem Sciences Inc. | 1.07 Million USD | 36.915% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.121% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 67.81% |
| Q BioMed Inc. | 8.13 Million USD | 91.629% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.179% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 86.77% |
| Biomind Labs Inc. | 1.49 Million USD | 54.569% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.427% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 92.47% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 96.301% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 52.517% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -379.14% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -238.528% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 88.151% |
| GB Sciences, Inc. | 5.41 Million USD | 87.433% |
| Alpha Cognition Inc. | 7.16 Million USD | 90.497% |
| HST Global, Inc. | 593.59 Thousand USD | -14.697% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 45.931% |
| Halberd Corporation | 728.71 Thousand USD | 6.571% |
| Enzolytics Inc. | 365.26 Million USD | 99.814% |
| Agentix Corp. | 2.51 Million USD | 72.881% |
| Resverlogix Corp. | 67.39 Million USD | 98.99% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 18.826% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.847% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 60.278% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 97.249% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 94.28% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 81.424% |
| AVAX Technologies, Inc. | 3.99 Million USD | 82.952% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2369.564% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.949% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -185.281% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 81.768% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 74.892% |
| Kadimastem Ltd | 3.5 Million USD | 80.575% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -917.248% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.645% |
| BioStem Technologies, Inc. | 15.9 Million USD | 95.719% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -46.511% |
| LadRx Corporation | 2.2 Million USD | 69.06% |
| Cell Source, Inc. | 15.8 Million USD | 95.693% |
| Regen BioPharma, Inc. | 5.45 Million USD | 87.525% |
| Regen BioPharma, Inc. | 5.45 Million USD | 87.525% |
| NovAccess Global Inc. | 7.86 Million USD | 91.339% |
| Affymax, Inc. | 8.87 Million USD | 92.325% |
| Itoco Inc. | 1.65 Million USD | 58.816% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 66.814% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 88.745% |
| Mobile Lads Corp. | 1.31 Million USD | 48.166% |
| CytoDyn Inc. | 127.89 Million USD | 99.468% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1528.828% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 56.534% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 93.836% |
| SYBLEU INC | 681.41 Thousand USD | 0.085% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 88.842% |
| International Stem Cell Corporation | 5.27 Million USD | 87.098% |
| Bioxytran, Inc. | 3.24 Million USD | 79.048% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -8.793% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 85.254% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.339% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.942% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 66.385% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 87.571% |
| Neutra Corp. | 973.52 Thousand USD | 30.065% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.654% |
| PureTech Health plc | 125.58 Million USD | 99.458% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 81.879% |
| IXICO plc | 1.9 Million USD | 64.172% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 96.684% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.341% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Cellectis S.A. | 249.36 Million USD | 99.727% |